Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: beta-lactamase inhibitors - Mirati Therapeutics

Drug Profile

Research programme: beta-lactamase inhibitors - Mirati Therapeutics

Alternative Names: MG 2121; MG 2204; MG 2394; MG 2907; MG 2913; MG 3394; MG 84760; MG 96077

Latest Information Update: 05 Jul 2013

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MethylGene
  • Class Small molecules
  • Mechanism of Action Beta lactamase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • Available For Licensing Yes

Highest Development Phases

  • Suspended Bacterial infections

Most Recent Events

  • 28 Jun 2013 Mirati Therapeutics is now the parent company of MethylGene
  • 02 Sep 2010 Preclinical development is ongoing in Canada
  • 14 Sep 2009 Pharmacodynamics and drug interactions data from a preclinical trial in Bacterial infections presented at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2009)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top